Genmab — Juli 2018
-
Tak til alle for de pæne. Dem er jeg meget glad for

-
bibob...I modsætning til de andre dage her på det sidste, så har vi ikke i dag fået de sædvanlige dyk i kursen efter stigningen. Et luk over de 1.140 kan/vil være et godt afsæt for positiv udvikling i de kommende dage.
-
Månedsgrafen ser flot og sund ud. Der er ikke mange flade etaper undervejs.
-
Nivolumab (opdivo) with Dara trial updated https://clinicaltrials.gov/ct2/history/NCT03098550?A=19&B=20&C=merged
-
Trial of Dara in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) was withdrawn, it was supposed to start this month
https://clinicaltrials.gov/ct2/history/NCT03207542?A=6&B=7&C=merged -
Danske købere er på ferie. Næst største køber efter A/B er svenske Avanza med hele 3 stk. aktier.

-
Altså netto efter køb af 10 stk og salg af 7.
-
Ligner et fornuftigt luk. Det mener Avanza også - og har derfor købt et stk. ekstra aktie.
-

-
Kinase inhibitor advances in MM: predictive biomarkers & efficacy of daratumumab http://www.oncologytube.com/video/kinase-inhibitor-advances-in-mm-predictive-biomarkers-efficacy-of-daratumumab/10004733
-
Trial represents ‘bold move’ for treatment of newly diagnosed myeloma - https://www.healio.com/hematology-oncology/myeloma/news/online/{1ebabaf8-6883-4567-8253-bc4ce2e72ecf}/trial-represents-bold-move-for-treatment-of-newly-diagnosed-myeloma
-
from Seattle Genetics Q2 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=RssLanding&cat=news&id=2360357
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind